| Name | Title | Contact Details |
|---|---|---|
Obi Nwokorie |
EVP, Alternative Credit Products and CIO | Profile |
Chun Li |
Senior Vice President - Securitized Product | Profile |
Since 2002, Colby Resources has established a tradition of trust among its local and regional clients. High standards attract good people. While recruiting for professionals in human resources, finance, oil & gas and other industries at the executive, technological and administrative level, Colby Resources provides excellence in service. We believe that chemistry between client and candidate is as fundamentally important as education and experience. Knowing our clients, their history and culture, where they’ve been and where they’re going and identifying the right candidate to compliment the organization is our formula for success.
Northwest Central Dispatch System is a Arlington Heights, IL-based company in the Business Services sector.
Pricer is the world leader in providing electronic shelf labelling solutions to retailers. The Pricer solution provides high-speed updates of your price and product information to your digital shelf labels, with the best readability and contrast of all labels worldwide. Whatever your store size, Pricer has an affordable, smart solution for improving your store margins and increasing customer satisfaction.
The team at Brain Scientific has made it our mission to build a complete Neurology EEG EcoSystem, offering two distinct devices, the NeuroCap and the NeuroEEG to streamline EEG prep, testing, and diagnosis of neurological disorders
Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.